Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

[1]  J. Ryu.  Faculty Opinions recommendation of The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  U. Pastorino,et al.  Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules , 2016, Virchows Archiv.

[3]  N. Socci,et al.  Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets , 2016, Clinical Cancer Research.

[4]  Delong Liu,et al.  Second- and third-generation ALK inhibitors for non-small cell lung cancer , 2016, Journal of Hematology & Oncology.

[5]  F. Cappuzzo,et al.  Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. , 2016, Lung cancer.

[6]  J. Shih,et al.  East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL) , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[7]  S. Hwang,et al.  Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma , 2016, BMC Cancer.

[8]  B. Solomon,et al.  FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies , 2015, Cell Death Discovery.

[9]  D. Lin,et al.  Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Popper,et al.  Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival , 2015, Virchows Archiv.

[11]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Yanxia Guo,et al.  Novel Immune Check-Point Regulators in Tolerance Maintenance , 2015, Front. Immunol..

[13]  R. Gentzler,et al.  Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). , 2015, Translational lung cancer research.

[14]  M. Frattini,et al.  Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type? , 2015, Oncotarget.

[15]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[16]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[17]  Joungho Han,et al.  Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma , 2015, Modern Pathology.

[18]  T. Stinchcombe.  Faculty Opinions recommendation of Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. , 2014 .

[19]  M. Kris,et al.  Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. , 2014, Clinical lung cancer.

[20]  J. Engelman,et al.  Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer , 2014, Clinical Cancer Research.

[21]  J. Liu,et al.  Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity , 2014, Proceedings of the National Academy of Sciences.

[22]  C. Dooms,et al.  Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Tingjun Hou,et al.  P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape , 2014, PLoS Comput. Biol..

[24]  Li Zhang,et al.  Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. , 2013, European journal of cancer.

[25]  I. Plaza-Menacho,et al.  Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase , 2013, Molecular and Cellular Endocrinology.

[26]  R. Olsen,et al.  Lung cancer biomarkers: present status and future developments. , 2013, Archives of pathology & laboratory medicine.

[27]  J. V. van Meerbeeck,et al.  BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer , 2013, Expert opinion on investigational drugs.

[28]  G. Webersinke,et al.  Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer , 2013, memo - Magazine of European Medical Oncology.

[29]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, Archives of pathology & laboratory medicine.

[30]  M. Jin,et al.  Evaluation of ALK Rearrangement in Chinese Non-Small Cell Lung Cancer Using FISH, Immunohistochemistry, and Real-Time Quantitative RT- PCR on Paraffin-Embedded Tissues , 2013, PloS one.

[31]  M. Ladanyi,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[32]  Tatsuo Ito,et al.  Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions , 2012, Clinical Cancer Research.

[33]  M. Ladanyi,et al.  Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component , 2012, Molecular Cancer Therapeutics.

[34]  J. Christensen,et al.  Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation , 2012, Molecular Cancer Therapeutics.

[35]  T. Nakagawa,et al.  Ligand‐triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands , 2012, Cancer science.

[36]  Jun-ling Liu,et al.  Activation of notch‐1 enhances epithelial–mesenchymal transition in gefitinib‐acquired resistant lung cancer cells , 2012, Journal of cellular biochemistry.

[37]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[38]  William Pao,et al.  Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance , 2012, Science Translational Medicine.

[39]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[40]  M. Ladanyi,et al.  Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling , 2011, Molecular Cancer Therapeutics.

[41]  T. Clackson,et al.  Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen , 2011, Chemical biology & drug design.

[42]  A. Iafrate,et al.  Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers , 2011, PloS one.

[43]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[44]  Takayuki Kosaka,et al.  Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer , 2011, Journal of biomedicine & biotechnology.

[45]  Ryohei Katayama,et al.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.

[46]  A. Gazdar,et al.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.

[47]  P. Jänne,et al.  Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib , 2008, Clinical Cancer Research.

[48]  T. Kinney,et al.  Pulmonary hemorrhage and systemic lupus erythematosus. , 1978, The Journal of pediatrics.

[49]  Kol Jia Yong,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[50]  J. Bruey,et al.  Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. , 2011, Cancer genetics.

[51]  H. Popper,et al.  [Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer]. , 2011, Wiener klinische Wochenschrift.

[52]  Haiquan Chen,et al.  Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma , 2014, OncoTargets and therapy.